Skip to content

Early Bolus Surfactant Replacement Therapy Versus Standard Care in Term Neonates With Meconium Aspiration Syndrome

Early Bolus Surfactant Replacement Therapy Versus Standard Care in Term (>=37 Weeks) Neonates With Actant Replacement Therapy Versus Standard Care in Term Neonates With Meconium Aspiration Syndrome: An Open Label Randomized Control Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06090981
Enrollment
60
Registered
2023-10-19
Start date
2022-03-12
Completion date
2024-03-12
Last updated
2024-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meconium Aspiration Syndrome, Surfactant Dysfunction

Brief summary

The objective of the study is to compare the total duration of respiratory support in term neonates (≥37weeks) with meconium aspiration syndrome, who are provided early(≤2hr) bolus surfactant therapy versus standard care.

Detailed description

Enrolled participants will be randomly assigned to one of two study groups: 1. early(≤2hr) bolus surfactant replacement therapy or 2. standard care Intervention group: The neonates enrolled in this group will receive early bolus surfactant replacement therapy within 2hr of life. Control group: The neonates enrolled in this group will receive standard care according to standard unit protocol

Interventions

Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg

Sponsors

Lady Hardinge Medical College
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Minutes to 2 Hours
Healthy volunteers
No

Inclusion criteria

* Gestation age ≥ 37 week * Cephalic presentation * Singleton pregnancy * Age \< 2 hours * Baby delivered through meconium stained amniotic fluid * Presence of respiratory distress (DOWNE's score ≥4)

Exclusion criteria

* Major congenital malformation * Antenatal diagnosed CHD * Hydrops fetalis * Air leaks before enrolment

Design outcomes

Primary

MeasureTime frameDescription
Duration of Total respiratory supportBirth to 28 daysCombined duration of invasive + non invasive ventilation

Secondary

MeasureTime frameDescription
Proportion of neonates requiring mechanical ventilationBirth to 28 daysThe babies will be assessed for the need for mechanical ventilation as per standard protocol
Proportion of neonates requiring Non Invasive VentilationBirth to 28 daysThe babies will be assessed for the need for non invasive ventilation as per standard protocol
Duration of Mechanical VentilationBirth to 28 daysTotal duration of Mechanical Ventilation in days
Severity of respiratory distressBirth to 28 daysThe severity of respiratory distress will be assessed using Downe's score. These parameters will be documented hourly within first 2 hours before surfactant replacement and in post lavage unto first 24 hrs, 2 hourly unto 48 hrs, and 4 holy thereafter till cessation of respiratory distress
ComplicationsBirth to 28 daysIncidence of PPHN, Pneumothorax, HIE, sepsis, airlocks,
MortalityBirth to 28 daysAll cause mortality
Duration of hospital stayBirth to 28 daysTotal duration of hospital stay in days
Duration of oxygen therapyBirth to 28 daysThe duration of oxygen therapy, mode of delivery, Fio2 and flow rates will be documented hourly within first 2 hours before surfactant replacement and in post lavage unto first 24 hrs, 2 hourly unto 48 hrs, and 4 holy thereafter till cessation of respiratory distress

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026